Neurodegenerative Disorders Research Pty Ltd
4 Lawrence Avenue, West Perth WA 6005
ABN: 86 139 590 319
Phone: (08) 9481 6293
Fax: (08) 9481 6294
Email: research@ndr.org.au
Web: www.ndr.org.au

TRx Alzheimer's Disease Study

Aim

To demonstrate the clinical efficacy of at least one dose of Leuco-methylthioninium bis (hydromethanesulfonate) (LMTM) in mild to moderate Alzheimer's disease and to determine its safety and tolerability.

Phase III

A global randomized, double-blind, placebo-controlled, parallel-group, 12-month trial of LMTM in subjects with mild to moderate Alzheimer's disease.

Hypothesis

Microtubular associated protein tau forms neurofibrillary tangles, a critical component of the pathology of Alzheimer's disease. LMTM dissolves toxic tau proteins and slows the progression of Alzheimer's disease.

Status

Now enrolling moderate subjects only

Study Code: TRx 237-015

Ethics approval

Bellberry Ethics Committee

Funding

TauRx Therapeutics

Criteria

To be eligible for this study subjects must:

- be less than 90 years old,
- have a Mini-Mental State Examination (MMSE) score of 14–26, and
- have a carer for at least 6 hours per week who will accompany subject to visits.

Duration of study

15 months

Contact

Professor Peter K Panegyres
Principal Investigator
Neurodegenerative Disorders Research Pty Ltd
4 Lawrence Avenue, West Perth WA 6005
Phone: (08) 9481 6293
Fax: (08) 9481 6294
Email: research@ndr.org.au